Pulmonary surveillance using bronchoscopy and bronchoalveolar lavage during high-dose antineoplastic therapy

W. P. Vaughan, James Linder, R. Robbins, M. Arneson, S. I. Rennard

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Pulmonary failure is a major contributor to morbidity and mortality during marrow aplasia following high-dose antineoplastic therapy. For this reason, we initiated a pulmonary surveillance program for patients undergoing high-dose chemotherapy for leukemia or bone marrow transplantation. As part of this program, bronchoscopy with BAL was performed prior to therapy and at the onset of granulocytopenia. Thirty-three of the first 57 patients managed in this program developed some evidence of pulmonary complications. Twelve patients died in aplasia; all had pulmonary failure. Forty patients had clinically significant abnormalities on the bronchoscopy before treatment, including 12 of 19 patients who had normal findings on chest x-ray films, physical examination, and pulmonary function testing, and no fever. Twenty-seven patients had clinically significant abnormal bronchoscopy or BAL at the onset of granulocytopenia. Thirteen patients required additional bronchoscopy. No patient required an open lung biopsy. Pulmonary surveillance using bronchoscopy with BAL is useful in the detection of pulmonary disease prior to the initiation of and following high-dose antineoplastic therapy.

Original languageEnglish (US)
Pages (from-to)105-111
Number of pages7
JournalChest
Volume99
Issue number1
DOIs
StatePublished - Jan 1 1991

Fingerprint

Bronchoscopy
Bronchoalveolar Lavage
Antineoplastic Agents
Lung
Dimercaprol
Agranulocytosis
Therapeutics
Motion Pictures
Bone Marrow Transplantation
Lung Diseases
Physical Examination
Leukemia
Fever
Thorax
Bone Marrow
X-Rays
Morbidity
Biopsy
Drug Therapy
Mortality

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Pulmonary surveillance using bronchoscopy and bronchoalveolar lavage during high-dose antineoplastic therapy. / Vaughan, W. P.; Linder, James; Robbins, R.; Arneson, M.; Rennard, S. I.

In: Chest, Vol. 99, No. 1, 01.01.1991, p. 105-111.

Research output: Contribution to journalArticle

Vaughan, W. P. ; Linder, James ; Robbins, R. ; Arneson, M. ; Rennard, S. I. / Pulmonary surveillance using bronchoscopy and bronchoalveolar lavage during high-dose antineoplastic therapy. In: Chest. 1991 ; Vol. 99, No. 1. pp. 105-111.
@article{c51a9a91eaab4ab48ad8d19b661ca67d,
title = "Pulmonary surveillance using bronchoscopy and bronchoalveolar lavage during high-dose antineoplastic therapy",
abstract = "Pulmonary failure is a major contributor to morbidity and mortality during marrow aplasia following high-dose antineoplastic therapy. For this reason, we initiated a pulmonary surveillance program for patients undergoing high-dose chemotherapy for leukemia or bone marrow transplantation. As part of this program, bronchoscopy with BAL was performed prior to therapy and at the onset of granulocytopenia. Thirty-three of the first 57 patients managed in this program developed some evidence of pulmonary complications. Twelve patients died in aplasia; all had pulmonary failure. Forty patients had clinically significant abnormalities on the bronchoscopy before treatment, including 12 of 19 patients who had normal findings on chest x-ray films, physical examination, and pulmonary function testing, and no fever. Twenty-seven patients had clinically significant abnormal bronchoscopy or BAL at the onset of granulocytopenia. Thirteen patients required additional bronchoscopy. No patient required an open lung biopsy. Pulmonary surveillance using bronchoscopy with BAL is useful in the detection of pulmonary disease prior to the initiation of and following high-dose antineoplastic therapy.",
author = "Vaughan, {W. P.} and James Linder and R. Robbins and M. Arneson and Rennard, {S. I.}",
year = "1991",
month = "1",
day = "1",
doi = "10.1378/chest.99.1.105",
language = "English (US)",
volume = "99",
pages = "105--111",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "1",

}

TY - JOUR

T1 - Pulmonary surveillance using bronchoscopy and bronchoalveolar lavage during high-dose antineoplastic therapy

AU - Vaughan, W. P.

AU - Linder, James

AU - Robbins, R.

AU - Arneson, M.

AU - Rennard, S. I.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Pulmonary failure is a major contributor to morbidity and mortality during marrow aplasia following high-dose antineoplastic therapy. For this reason, we initiated a pulmonary surveillance program for patients undergoing high-dose chemotherapy for leukemia or bone marrow transplantation. As part of this program, bronchoscopy with BAL was performed prior to therapy and at the onset of granulocytopenia. Thirty-three of the first 57 patients managed in this program developed some evidence of pulmonary complications. Twelve patients died in aplasia; all had pulmonary failure. Forty patients had clinically significant abnormalities on the bronchoscopy before treatment, including 12 of 19 patients who had normal findings on chest x-ray films, physical examination, and pulmonary function testing, and no fever. Twenty-seven patients had clinically significant abnormal bronchoscopy or BAL at the onset of granulocytopenia. Thirteen patients required additional bronchoscopy. No patient required an open lung biopsy. Pulmonary surveillance using bronchoscopy with BAL is useful in the detection of pulmonary disease prior to the initiation of and following high-dose antineoplastic therapy.

AB - Pulmonary failure is a major contributor to morbidity and mortality during marrow aplasia following high-dose antineoplastic therapy. For this reason, we initiated a pulmonary surveillance program for patients undergoing high-dose chemotherapy for leukemia or bone marrow transplantation. As part of this program, bronchoscopy with BAL was performed prior to therapy and at the onset of granulocytopenia. Thirty-three of the first 57 patients managed in this program developed some evidence of pulmonary complications. Twelve patients died in aplasia; all had pulmonary failure. Forty patients had clinically significant abnormalities on the bronchoscopy before treatment, including 12 of 19 patients who had normal findings on chest x-ray films, physical examination, and pulmonary function testing, and no fever. Twenty-seven patients had clinically significant abnormal bronchoscopy or BAL at the onset of granulocytopenia. Thirteen patients required additional bronchoscopy. No patient required an open lung biopsy. Pulmonary surveillance using bronchoscopy with BAL is useful in the detection of pulmonary disease prior to the initiation of and following high-dose antineoplastic therapy.

UR - http://www.scopus.com/inward/record.url?scp=0026014039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026014039&partnerID=8YFLogxK

U2 - 10.1378/chest.99.1.105

DO - 10.1378/chest.99.1.105

M3 - Article

C2 - 1984939

AN - SCOPUS:0026014039

VL - 99

SP - 105

EP - 111

JO - Chest

JF - Chest

SN - 0012-3692

IS - 1

ER -